Biotech Values

[jq1234]

I wonder if the results reported for Xgeva in this trial regarding prevention of bone mets may cause EXEL to be more inclined to ultimately focus the development of XL184 on treating bone mets, as opposed to prevention, via trying to demonstrate a survival advantage and/or pain benefit?

EXEL announced during R&D day that the plan for pre-mCRPC is for future - they have to do dose ranging study for this indication. They can't use current dose for this indication. This indication is going to take years - denosumab trial for this indication lasted almost 5 years.

XL184 immediate plan is for chemo-treated mCRPC. Even non-chemo-treated mCRPC is not in immediate plan. You go with the qucikest way to market indication first.

Look at presentation 2 slide number 10.